Jim Simons
GMAB icon

Jim Simons’s Genmab GMAB Stock Holding History

Jim Simons’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118M Buy
4,414,550
+921,700
+26% +$27.6M 0.19% 118
2025
Q4 		$108M Buy
3,492,850
+671,307
+24% +$20.9M 0.17% 136
2025
Q3 		$86.5M Buy
2,821,543
+54,793
+2% +$1.34M 0.11% 194
2025
Q2 		$57.2M Buy
2,766,750
+504,400
+22% +$10.4M 0.08% 294
2025
Q1 		$44.3M Buy
2,262,350
+336,200
+17% +$7.05M 0.07% 360
2024
Q4 		$40.2M Buy
1,926,150
+139,722
+8% +$3.07M 0.06% 393
2024
Q3 		$43.6M Buy
1,786,428
+323,969
+22% +$8.66M 0.07% 369
2024
Q2 		$36.8M Buy
1,462,459
+103,859
+8% +$2.94M 0.06% 380
2024
Q1 		$40.6M Sell
1,358,600
-136,200
-9% -$4M 0.06% 367
2023
Q4 		$47.6M Buy
1,494,800
+320,800
+27% +$10.1M 0.07% 310
2023
Q3 		$41.4M Buy
1,174,000
+334,900
+40% +$12.8M 0.07% 316
2023
Q2 		$31.9M Sell
839,100
-210,500
-20% -$8.39M 0.05% 457
2023
Q1 		$39.6M Sell
1,049,600
-141,100
-12% -$5.42M 0.05% 414
2022
Q4 		$50.5M Buy
1,190,700
+274,300
+30% +$11.3M 0.07% 333
2022
Q3 		$29.4M Sell
916,400
-63,800
-7% -$2.24M 0.04% 498
2022
Q2 		$31.8M Sell
980,200
-108,300
-10% -$3.51M 0.04% 511
2022
Q1 		$39.4M Buy
1,088,500
+14,100
+1% +$484K 0.05% 428
2021
Q4 		$42.5M Buy
1,074,400
+175,600
+20% +$7.32M 0.05% 380
2021
Q3 		$39.3M Buy
898,800
+13,900
+2% +$624K 0.05% 389
2021
Q2 		$36.1M Sell
884,900
-107,400
-11% -$4.14M 0.05% 448
2021
Q1 		$32.6M Sell
992,300
-318,900
-24% -$12M 0.04% 529
2020
Q4 		$53.3M Sell
1,311,200
-352,000
-21% -$13.2M 0.06% 325
2020
Q3 		$60.9M Buy
1,663,200
+560,103
+51% +$20.3M 0.06% 331
2020
Q2 		$37.4M Buy
1,103,097
+954,697
+643% +$26M 0.03% 520
2020
Q1 		$3.15M Buy
+148,400
New +$3.31M ﹤0.01% 1824

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jim Simons's GMAB Position: Q1 2026 in Review

Jim Simons increased its Genmab (GMAB) stake by 26% in Q1 2026, buying an estimated $27.6M and bringing the position to 4,414,550 shares worth $118M. The position accounts for 0.19% of the portfolio, ranked #118.

Jim Simons first reported a position in GMAB in Q1 2020 and has held it in 25 quarters since. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Jim Simons held 4,414,550 shares of Genmab worth $118M as of Q1 2026.
  • Jim Simons bought 921,700 Genmab shares in Q1 2026, an estimated $27.6M.
  • Genmab made up 0.19% of Jim Simons's portfolio in Q1 2026, its #118 holding.
  • Jim Simons first reported a position in Genmab in Q1 2020 and has held it in 25 quarters since.
  • 274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.